VRG Therapeutics
Primary tabs
About your organization / profile
VRG Therapeutics (VRG Tx) is an original biopharmaceutical R&D company headquartered in Budapest.
VRG Tx leverages its unique drug discovery platform to create cures for diseases through novel mechanisms of action that conventional biopharmaceutical approaches cannot. The VRG Tx platform is verified by our internal pipeline with proven in vivo results in relevant animal models. It can reduce hit validation time to 6 months while reducing preclinical development costs by up to 40%.
VRG Tx’s miniprotein-based portfolio addresses major unmet clinical needs in autoimmune diseases, inflammation, and oncological indications, while also incubating two assets with promising applications, one in migraine prophylaxis (VRG-145) and another one as a CNS medication.
VRG's lead asset is a best-in-class Kv1.3 inhibitor addressing autoimmune diseases (Atopic dermatitis, Psoriasis, IBD) with proven in vivo efficacy.
Network (0)
There are no organizations in the network.
Recent activities
VRG Therapeutics has taken its fundraising offline.
The pitchdeck document has been updated in the dataroom.
The dataroom has been updated.
VRG Therapeutics has published fundraising documents.
Csikai Tamas has joined VRG Therapeutics.